18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth | Zendy

Mine Araz | Zendy; Derya Çayır | Zendy

Open Access

18F-Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography for Other Thyroid Cancers: Medullary, Anaplastic, Lymphoma and So Forth

Author(s) -

Mine Araz,

Derya Çayır

Publication year - 2017

Publication title -

molecular imaging and radionuclide therapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.292

H-Index - 7

eISSN - 2147-1959

pISSN - 2146-1414

DOI - 10.4274/mirt.60783

Subject(s) - medicine , positron emission tomography , nuclear medicine , thyroid , fluorodeoxyglucose , medullary cavity , lymphoma , medullary thyroid cancer , positron emission tomography computed tomography , radiology , thyroid carcinoma , pathology

Positron emission tomography/computed tomography (PET/CT) with 18 F-fluorodeoxyglucose (FDG) is used in staging, restaging, and evaluation of therapy response in many cancers as well as differentiated thyroid carcinomas especially in non-iodine avid variants. Its potential in less frequent thyroid tumors like medullary, anaplastic thyroid cancers, thyroid lymphoma and metastatic tumors of the thyroid however, is not well established yet. The aim of this review is to provide an overview on the recent applications and indications of 18 F-FDG PET/CT in these tumors and to focus on the controversies in the clinical setting.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research